IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo4047.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report
Palbociclib + fulvestrant in a positive hormonal receptors metastatic breast cancer
Show Less
1 Oncology Unit Gard Cancer Institute, NÎmes, France
Eur. J. Gynaecol. Oncol. 2018, 39(6), 1032–1033;
Published: 10 December 2018

Palbocilcib is a first-in-class drug, that demonstrated in several studies, improvements in progression-free-survival, in combination with endocrine therapy. Palbociclib with fulvestrant improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. The author reports the case of a 63-year-old metastatic breast cancer patient, positive for hormonal receptors, that had received multiple chemotherapy regimens. She was treated with palbociclib plus fulvestrant. Three months later she obtained partial response. However she also experienced side-effects such as grade IV neutropenia and grade III thrombopenia, that led to palbociclib reduction.
breast cancer
Positive hormonal receptors
Back to top